May 21, 2020 / 10:12 PM / in 5 days

BRIEF-Tetraphase Pharmaceuticals Says Got Revised Proposal From Melinta Therapeutics

May 21 (Reuters) - Tetraphase Pharmaceuticals Inc:

* TETRAPHASE PHARMACEUTICALS - GOT A REVISED PROPOSAL FROM MELINTA THERAPEUTICS

* TETRAPHASE PHARMA - UNDER REVISED PROPOSAL, MELINTA TO BUY CO FOR ABOUT $27.0 MILLION IN CASH, PLUS $12.5 MILLION IN CASH PAYABLE UNDER CONTINGENT VALUE RIGHTS

* TETRAPHASE PHARMA - UNDER REVISED MELINTA PROPOSAL, UPFRONT CASH CONSIDERATION WOULD BE $1.21/SHARE OF TETRAPHASE COMMON STOCK

* TETRAPHASE - UNDER REVISED PROPOSAL, UPFRONT CASH CONSIDERATION TO BE $1.75/SHARE OF CO’S COMMON STOCK UNDERLYING COMMON STOCK WARRANTS ISSUED IN 2019

* TETRAPHASE - UNDER REVISED PROPOSAL, UPFRONT CASH CONSIDERATION TO BE $1.75/SHARE OF CO'S COMMON STOCK UNDERLYING COMMON STOCK WARRANTS ISSUED IN 2020 Source text: (bit.ly/3cW7IW4) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below